Trials / Terminated
TerminatedNCT00080002
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
Effectiveness and Safety Study of Pegamotecan (PEG-Camptothecin) in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastroesophageal Junction Who Have Relapsed or Progressed Following a Previous Chemotherapy Treatment
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Enzon Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of pegamotecan (PEG-camptothecin) in patients with pathologically-diagnosed locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction who have relapsed or progressed following one prior chemotherapy treatment regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegamotecan |
Timeline
- Start date
- 2003-12-01
- First posted
- 2004-03-23
- Last updated
- 2012-09-06
Source: ClinicalTrials.gov record NCT00080002. Inclusion in this directory is not an endorsement.